Bellevue Life Sciences Acquisition - Warrants (09/02/2028) OverviewTrack Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s operating income ($-16M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
As of the most recent data (September 2026), BLACW shows a operating income of $-16M. That compares with $-14M in the prior-year period — down 14.6% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BLACW's operating income is now $-16M (was $-14M) — a 14.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bellevue Life Sciences Acquisition - Warrants (09/02/2028) is outperforming or lagging.
Tracking BLACW's operating income over time shows whether Bellevue Life Sciences Acquisition - Warrants (09/02/2028) is scaling, shrinking, or reshaping that part of the business. The current reading is $-16M That compares with $-14M in the prior-year period — down 14.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has Bellevue Life Sciences Acquisition - Warrants (09/02/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-16M) with ownership activity and broader fundamentals.
